PipelineReview. Business Intellegence Center

All News

28 August 2012

FDA Lifts Clinical Hold on Lpath’s iSONEPAntibodies

28 August 2012

Morphotek, Inc. Announces Initiation of MORAb-004 Phase II Study in Metastatic Soft Tissue SarcomaAntibodies

27 August 2012

Genzyme Provides Update on U.S. LEMTRADA FilingAntibodies

27 August 2012

New Data from Phase III EMILIA Study Showed Genentech’s Trastuzumab Emtansine (T-DM1) Significantly Improved Survival of People With HER2-Positive Metastatic Breast CancerAntibodies

24 August 2012

Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell CarcinomaAntibodies

24 August 2012

Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer’s DiseaseAntibodies

23 August 2012

Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid ArthritisAntibodies

22 August 2012

Symphogen Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in BLOOD JournalAntibodies

19 August 2012

AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial PlansAntibodies

16 August 2012

Apexigen Announces the Filing of an IND by its Partner, 3SBioAntibodies

15 August 2012

MORPHOTEK OPENS PILOT ANTIBODY MANUFACTURING PLANTAntibodies

11 August 2012

Crucell and Scripps Research Discover and Describe Broad-Spectrum Antibodies Against Influenza B, a Crucial Link in Development of Universal Flu Therapies and VaccineAntibodies

11 August 2012

Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an Aggressive Form of Brain Cancer Lived without Their Disease WorseningAntibodies

11 August 2012

FDA Approves Lucentis (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)Antibodies

9 August 2012

AmorChem invests in a novel cholesterol-lowering biologic product targeting PCSK9Antibodies

9 August 2012

Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic CancerAntibodies

8 August 2012

BTG Announces Data from Phase IIb Study of AZD9773Antibodies

7 August 2012

Pfizer Announces Co-Primary Clinical Endpoints Not Met In Second Phase 3 Bapineuzumab Study In Mild-To-Moderate Alzheimer’s Disease Patients Who Do Not Carry The Apoe4 GenotypeAntibodies

7 August 2012

Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimer’s DiseaseAntibodies

4 August 2012

U.S. FDA Approves ZALTRAP (ziv-aflibercept) After Priority Review for Previously Treated Metastatic Colorectal CancerAntibodies

2 August 2012

Baxter Confirms Receipt of Complete Response Letter on HyQAntibodies

31 July 2012

Regeneron Receives Complete Response Letter From FDA for ARCALYST (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering TherapiesAntibodies

31 July 2012

Mersana Therapeutics Raises $27M to Advance Fleximer Antibody-drug ConjugatesAntibodies

30 July 2012

New Published Paper Shows Efficacy of Lpath’s Anti-LPA Antibody, Lpathomab, in Spinal Cord Injury ModelsAntibodies

28 July 2012

SuppreMol begins development of Anti-IL-3 monoclonal antibody to diagnose and treat early stage Rheumatoid ArthritisAntibodies

27 July 2012

Genentech Reports Second Positive Study of ACTEMRA Given by Subcutaneous Injection to Patients with Rheumatoid ArthritisAntibodies

26 July 2012

FDA Advisory Committee Unanimously Recommends Approval of Lucentis for Treatment of Diabetic Macular Edema (DME)Antibodies

26 July 2012

Apogenix GmbH: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial in Treatment of Recurrent GlioblastomaAntibodies

24 July 2012

Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab Phase 3 ProgramAntibodies

22 July 2012

Millennium and Takeda Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS (brentuximab vedotin) in EuropeAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

SubscribeNewsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

SubscribeNewsletter new product alert

Featured reports

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review
Bispecific Antibodies for Immuno-Oncology & Other Diseases
DLL3-Targeted Immunotherapy Candidates Pipeline Review
Cadherin 17: A target opportunity to develop effector-enhanced drug modalities
2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
Report Package: Bispecific Antibodies
Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective
5T4-Targeted Immunotherapy Candidates Pipeline Review
2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount
Report Package: TCR-Based Antibody and T-Cell Immunotherapy